

ANAND AND ANAND

PARTNERS
N. K. ANAND
RAJ ANAND (1938-1992)
*PRAVIN ANAND
DEBBI GUPTA
BINNY KALRA
SAFIR ANAND
ARCHANA SHANKER
M. S. BHARATH
SAFIR KIRAN
VIDYA BHUSHAN MEHRISH
Dr. NEETI WILSON
VAISHALI MITTAL
VIDISHA GARG

DIRECTOR
RAJIV BHATTNAGAR
DEVINDER SINGH RAWAT

LITIGATION GROUP
AKASH SOMANI
ABHILASHA NAUTYAL
ACHUTHAN SREEKUMAR
ADITYA GUPTA
AMAN TANEJA
AYUSHI KIRAN
BHAGWATI PRASAD
D. NEHA REDDY
DHIRUV ANAND
DIVYA VIJAN
GEETANALI YESHANTHAN
GOWRI TIRUMURTI
GURPREET SINGH KAHLON
JAVA NEGI
KARAN KUMAR KAMRA
K. PREMCHANDAR
KRITI BALASUBRAMANIAN
MANISH BIALA
NAVANTARA SANYAL
NISHCHAL ANAND
NITIA THAKUR
NUPUR KUMAR
PRACHI AGARWAL
PUNEET AHUJA
RAHUL AKSHAYTRIJU
RAUNAQ KAMATH
RAHUL VATS
SHANTANU SAHAY
SHRAWAN CHOJRA
SHOBHIT AGRAWAL
T. SAIKSHMYA
TANVI MISRA
TUSHI MALHOTRA
UDITA PATRO
VIBHAV MITTAL

Mailing Address

B-41, NIZAMUDDIN EAST, NEW DELHI-110013 INDIA

Office Location

PLOT NO. 17A, SECTOR 16A, FILM CITY, NOIDA - 201301 (UP), INDIA

PHONES : 91-120-4059300 (100 Lines) FAX : 91-120-4243056 - 057; 91-120-2510020

email@anandandanand.com www.anandandanand.com

TRADEMARK GROUP
CHITRA SUBBIAH
CHRISTINE CHIRAMEL
DEVIKA BAHADUR
GAUTAM RAZDAN
MADHU REWARI
NUPUR SHARMA
REVANTA MATHUR
SANDHYA SINGH
SHRUTI KHIMTA
SHIVANI RAMMAL
SWATI SHARMA
YOGYATA SINGH

PATENTS GROUP
ABHISHEK MAGOTRA
AMITA ARORA
ARPIA KUSHRESTHA
DRISHI KAUR VILKHU
GITANJALI BHATTNAGAR
GITIKA SURI
KARISH GILGATI
NUPUR MATHANI
PRIYANKA DUBEY
RAKHEE SHARMA
RACHANA BISHNOI
SANDEEP KUMAR BHOLA
SHRADHA SINGH CHAUHAN
STUTI DHYANI

Our Ref : 17283/P-1

THE CONTROLLER OF PATENT
THE PATENT OFFICE
DELHI

11th April 2014

Kind Attn.: Dr. Nilanjana Mukherjee
Controller of Patent and Design

**Re: Pre-grant representation under Section 25(1)
in respect of Indian Patent Application No. 2899/DELNP/2005
Applicant: Abraxis BioScience, LLC
Opponent: NATCO Pharma Ltd.**

Ma'am,


This is with reference to the hearing before the Learned Controller on 1st April and 2nd April 2014.

We are enclosing herewith the additional affidavit of Dr. Neil Desai which clearly provides that as to why the comparison of efficacy was done by the applicant between old formulation and new formulation with a ratio 19:1/20:1 versus 9:1.


Additionally, the said affidavit also clarifies the nomenclature that has been used as being ABI-007 for nanoparticle albumin-bound paclitaxel products under different stages of development. There was no mention of these two issues in the pleadings of the opponent but in good faith in order to clarify any doubts the Learned Controller might have, we are filing the said affidavit.

Kindly take the said documents on record.

Yours faithfully


Archana Shanker

Encl: as stated above



V3 0.0 16\Patent Data\Hemlata\Archana maam\2014\April\Email.docx

CEO : Rajiv Maheshwari, CFO : Sanjeev Sharma, CIO : Subrato K Panda, Admin Head : Kavita Sabharwal
For enrolment numbers of Advocates see reverse



11 APR 2014

AFFIDAVIT OF DR. NEIL P. DESAI, C/o ABRAXIS BIOSCIENCE LLC OF LOS ANGELES, CALIFORNIA, USA

I, the above named Deponent do hereby solemnly affirm and declare as under:

1. I am the Vice President at Celgene, Inc., the parent company of Abraxis BioScience, LLC ("Abraxis"), the applicant/ assignee of Indian Patent Application No. 2899/DELNP/2005 (hereinafter referred to as "patent application"). Before Abraxis was acquired by Celgene, I was the Senior Vice President of Global Research and Development at Abraxis. A copy of my biography is attached hereto as Exhibit 1.
2. I have more than 20 years of experience in the research and development of drug delivery systems and biocompatible polymers. I was one of the individuals responsible for the development of Abraxis' nanoparticle-albumin bound (nab®) drug delivery platform and its product Abraxane®.
3. I am one of the named inventors of the above referenced patent application and am familiar with the technical features of the invention, the amended claims, and the specification.
4. In this declaration, I provide information about the nanoparticle albumin-bound paclitaxel products we developed and disclosed in the above referenced patent application and in WO00/71079.
5. Example 1 of WO00/71079 discloses a lab-scale preparation method of nanoparticle albumin bound paclitaxel composition by high pressure homogenization method. 30 mg paclitaxel was dissolved in 3 ml methylene chloride and added to 27 ml of 1% (w/v) albumin. The weight ratio of albumin to paclitaxel in the starting components was 9:1. Due to its poor water

solubility, paclitaxel is inherently lost during a preparation or manufacturing process which occurs in the aqueous state. In contrast, albumin, which is freely water soluble, remains in solution. Consequently more paclitaxel than albumin would be lost during the preparation process, which would alter the ratio of the components in the finished product. Taking into account loss of paclitaxel during the nanoparticle preparation process, the estimated albumin/paclitaxel ratio in the resulting nanoparticle albumin-bound paclitaxel composition was about 13.3:1. See Example 1 and page 36 of WO99/00113A1.

6. Because the experiment reported in Example 1 of WO00/70179 was on a very small lab scale using 30 mg paclitaxel (30 ml total volume), there was not sufficient nanoparticle composition made in Example 1 that could be used for further clinical studies.
7. The starting albumin/paclitaxel ratio was subsequently changed during the scaling-up process. Scaling-up of a pharmaceutical preparation manufacturing process from laboratory and bench scale to a manufacturing plant scale is usually done in a series of steps, each at a suitably larger scale than the previous scale, in order to determine the reproducibility of manufacturing and product quality in moving from the laboratory bench to the manufacturing plant. Changes in scale of equipment, processing time, process conditions, surface area of contact for the key components, and many other factors that change in going from small scale to larger scale, may affect the composition of the final product. Therefore, experimentation at different scales of manufacture were conducted and necessary adjustments were made during product development.
8. Examples 6 and 7 of WO00/71079 disclose a larger scale preparation method of albumin/paclitaxel nanoparticle composition by high pressure

homogenization using 225 mg paclitaxel (100 ml total volume). 225 mg paclitaxel was dissolved in 2.7 ml chloroform and 0.3 ml ethanol and then added to 97 ml 3% (w/v) albumin. The starting ratio of albumin to paclitaxel was about 13:1.

9. Example 16 of WO99/00113 provides a “Summary of the Presently Preferred Manufacturing Process: Starting with 1 gram Paclitaxel as the BDS.” 51.7 ml of 25% albumin was added to 379.3 ml water to make a total of 431 ml of 3% albumin. The starting ratio of albumin to paclitaxel was about 13:1. While the scale in Example 16 of WO99/00113 was still relatively small (444 ml total volume) compared to the manufacturing scale, the 13:1 starting ratio was indeed what we had used when manufacturing the nanoparticle albumin bound paclitaxel formulation (“old formulation”) before switching to a new formulation having a lower albumin/paclitaxel ratio (“new formulation”).
10. Exhibit 2 provides the Master Formula for a manufacture lot of the old formulation (Product No. 101150, Lot No. C199-005). As shown in Exhibit 2, the initial concentration of paclitaxel per mL of the total solution was 2.25 mg. The initial concentration of albumin per mL of the total solution was 30 mg (20% x 0.15 ml). This makes a starting albumin/paclitaxel ratio of about 13:1. Exhibit 3 provides the Certificate of Analysis for the old formulation (Product No. 101150, Lot No. C199-005). As shown in Exhibit 3, the amount of paclitaxel in the finished product was 32.7 mg/vial. The amount of albumin in the finished product was 644 mg/vial. This makes the albumin/paclitaxel ratio in the finished product to be about 19:1. This old formulation having a final albumin/paclitaxel ratio of about 19:1 was used in the clinical study discussed in the affidavits submitted by me and separately by Dr. Anindiya during the pre-grant opposition proceedings.

11. To make a nanoparticle albumin bound paclitaxel formulation having a desired albumin/paclitaxel ratio, one can use routine methods and experimentation to determine the starting ratio of albumin and paclitaxel needed for the process, by taking into account the percentage of paclitaxel loss during the manufacturing process.
12. ABI007 is a code name we used at Abraxis to designate the nanoparticle albumin bound paclitaxel products under development. The code name ABI007 is not tied to any specific formulation having a specific albumin/paclitaxel ratio. While we altered the albumin/paclitaxel ratio from 19:1 (old formulation) to 9:1 (new formulation) during product development, we continued to refer to the product as ABI007. The way we distinguished the old formulation from the new formulation was by using a unique manufacturing product code. For example, Exhibit 4 (an excerpt from an amendment to the Technical Report for Abraxane®) provides a table summarizing various ABI-007 lots used in characterization studies. Product Code No. 101150 refers to the old formulation, while Product Code No. 103350 refers to the new formulation.

DEPONENT



Neil P. Desai, Ph.D.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.